0000000000424993

AUTHOR

Carlos Ferre-aracil

showing 1 related works from this author

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

2021

INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid. There is scarce information outside of clinical trials. Therefore, we have assessed the effectiveness and adverse events of these treatments. METHODS: Data from patients included in the ColHai registry treated with OCA, fibrates, or both were recorded during a year, as well as adverse events and treatment discontinuation. RESULTS: Eighty-six patients were treated with OCA, 250 with fibrates (81% bezafibrate; 19% fenofibrate), and 15 with OCA plus fibrates. OCA group had baseli…

Malemedicine.medical_specialtyPROGNOSISChenodeoxycholic AcidPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFenofibrateInternal medicinemedicineHumansBIOCHEMICAL RESPONSEAdverse effectCIRRHOSISRetrospective StudiesFenofibrateBezafibrateHepatologybusiness.industryLiver Cirrhosis BiliaryGastroenterologyObeticholic acidMiddle AgedBEZAFIBRATEUrsodeoxycholic acideye diseasesDiscontinuationURSODEOXYCHOLIC ACIDClinical trialTreatment Outcomechemistry030220 oncology & carcinogenesisAlkaline phosphatase030211 gastroenterology & hepatologyFemaleBezafibratebusinessmedicine.drug
researchProduct